(Q37825532)

23 August 2017

1 reference

title

Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? (English)

1 reference

23 August 2017

Review article: chronic hepatitis B – anti‐viral or immunomodulatory therapy? (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

21 November 2024

1 reference

1 reference

1 reference

V. Rijckborst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21198707

21 November 2024

M. J. Sonneveld

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21198707

21 November 2024

H. L A. Janssen

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21198707

21 November 2024

language of work or name

English

0 references

publication date

29 December 2010

1 reference

full work available at URL

23 August 2017

https://hal.archives-ouvertes.fr/hal-00604414/file/PEER_stage2_10.1111%252Fj.1365-2036.2010.04555.x.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21198707

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2010.04555.x

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2010.04555.x

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Alimentary Pharmacology & Therapeutics

21 November 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

501-513

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Molecular virology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Endpoints of therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Antiviral resistance and hepatitis B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Actions of cytokines on the immune response and viral interactions: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Pegylated interferons for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04555.X

Hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Treatment of hepatitis B: who, when, and how?

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B

21 November 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2010.04555.X

21 November 2024

Identifiers

1 reference

23 August 2017

1 reference